Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Among authors: mcginniss j. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab.
Landmesser U, McGinniss J, Steg PG, Bhatt DL, Bittner VA, Diaz R, Dilic M, Goodman SG, Jukema JW, Loy M, Pećin I, Pordy R, Poulsen SH, Szarek M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Landmesser U, et al. Among authors: mcginniss j. Eur J Prev Cardiol. 2022 Oct 20;29(14):1842-1851. doi: 10.1093/eurjpc/zwac107. Eur J Prev Cardiol. 2022. PMID: 35708715
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes.
Moriarty PM, Steg PG, McGinniss J, Zeiher AM, White HD, Manvelian G, Pordy R, Loy M, Jukema JW, Harrington RA, Gray JV, Gorby LK, Goodman SG, Diaz R, Bittner VA, Bhatt DL, Szarek M, Schwartz GG; ODYSSEY OUTCOMES Investigators. Moriarty PM, et al. Among authors: mcginniss j. J Clin Lipidol. 2022 Sep-Oct;16(5):747-756. doi: 10.1016/j.jacl.2022.08.004. Epub 2022 Aug 23. J Clin Lipidol. 2022. PMID: 36153281 Free article. Clinical Trial.
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.
Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, Moriarty PM, Rubba P, Whitcomb DC, Banerjee P, Gewitz A, Gonzaga-Jauregui C, McGinniss J, Ponda MP, Pordy R, Zhao J, Rader DJ. Rosenson RS, et al. Among authors: mcginniss j. Nat Med. 2023 Mar;29(3):729-737. doi: 10.1038/s41591-023-02222-w. Epub 2023 Mar 6. Nat Med. 2023. PMID: 36879129 Free PMC article. Clinical Trial.
Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Brown D, et al. Among authors: mcginniss j. Schizophr Bull. 2019 Mar 7;45(2):350-359. doi: 10.1093/schbul/sby049. Schizophr Bull. 2019. PMID: 29718385 Free PMC article. Clinical Trial.
Multiple Imputation in Three or More Stages.
McGinniss J, Harel O. McGinniss J, et al. J Stat Plan Inference. 2016 Sep;176:33-51. doi: 10.1016/j.jspi.2016.04.001. Epub 2016 Apr 20. J Stat Plan Inference. 2016. PMID: 27647949 Free PMC article.
31 results